Human enteroviruses (HEVs), members of the Enterovirus genus of the family Picornaviridae, are common human pathogens associated with a wide spectrum of diseases. These range from asymptomatic infection to serious illness, especially in children (20) and the immunocompromised. Clinical syndromes include aseptic meningitis (1, 25) , encephalitis (8, 26) , fever and rash, acute flaccid paralysis (29) , and gastrointestinal and respiratory illness. Some HEVs (e.g., EV71) have caused large outbreaks in Southeast Asia (21) . Polioviruses (PVs) (including vaccine strains) have reemerged recently and have been associated with clinical disease (30) . Although Australia is "polio-free," there have been recent outbreaks of polio in nearby Indonesia (5) and recent importation of a case from Pakistan (31) .
The original classification of HEVs consisted of PVs, coxsackieviruses A (CVA) and B (CVB), and echoviruses (E), based on biological activity and disease. Conventional approaches for detecting and characterizing HEVs are based on the time-consuming and labor-intensive procedures of viral isolation in cell culture and neutralization using reference antisera (7) . Current classification of the over 100 HEV serotypes (http://www.picornaviridae.com) divides the members of HEV genera into four species (HEV-A, HEV-B, HEV-C, and HEV-D), based on genome organization, sequence similarity, and biological properties (23) . At present, molecular typing methods largely depend on reverse transcription-PCR (RT-PCR) amplification and nucleotide sequencing of the entire or 3Ј half of the VP1 gene (23) . Comparison of the VP1 sequence with databases of VP1 sequences of HEV prototype and variant strains (18) allows genotype assignation. Other molecular methods that assist in serotype-specific identification include multiplex real-time hybridization probe RT-PCR for specific detection and differentiation of enterovirus type 71 (EV71) and CVA16 (28) , combined multiplex RT-PCR and microarray assay to detect and differentiate EV71 and CVA16 (4), molecular characterization of PV strains by RT-PCR-restriction fragment length polymorphisms (2) , and an integrated micro-RT-PCR system for automatic detection of microorganisms, including EV71 (11) . Experience with microwell oligonucleotide arrays (27) and other non-sequencing-based molecular methods to genotype other HEV serotypes is limited.
The 20 most frequent HEV serotypes identified at the reference virology laboratory of the Centre for Infectious Diseases and Microbiology (CIDM) in New South Wales, Australia, from 1979 to 2007 included HEV-A (CVA16 and EV71), HEV-B (E3, -6, -7, -9, -11, -14, -17, -18, and -30, CVB1, -2, -3, -4, and -5, and CVA9), and HEV-C (PV1, -2, and -3) serotypes. These 20 serotypes accounted for 87.1% of all HEVs referred for typing during this period.
In order to establish a quick, accurate, and cost-effective on July 10, 2017 by guest http://jcm.asm.org/ method to characterize different isolates belonging to these common serotypes, we developed an HEV RT-PCR-reverse line blot (RLB) assay, using modifications from previously published RLB assays (9, 10, 32, 33) .
MATERIALS AND METHODS

Viruses.
Our laboratory database contained 6,383 HEVs isolated between 1979 and 2007. Isolates were obtained by inoculation of clinical specimens, including specimens where HEV had been detected by real-time fluorescence PCR (24) , into cultures of primary monkey kidney cells and a variety of continuous cell lines, including A549 (human lung carcinoma), MRC-5 (human embryonic lung fibroblast), and RD (human rhabdomyosarcoma) cells. The serotype of each isolate was identified by neutralization with serotype-specific horse antisera, originally purchased from the National Institute of Allergy and Infectious Diseases (Bethesda, MD). Virus isolates were stored as unpurified cell culture supernatants at Ϫ70°C.
In this study, 132 HEV isolates collected from 1990 to 2007 and belonging to the commonest 20 serotypes were randomly selected from 6,383 HEV isolates for testing by RT-PCR-RLB. Of these 132 isolates, 37 (one or more examples of the 20 commonest serotypes) were also used for sequencing of the VP1 gene.
Primer design for VP1. To amplify the VP1 region, the VP1 sequences of all 85 known prototype HEV strains (23) plus EV94 (GenBank accession no. EF107097) were aligned using the ClustalW tool provided in Biomanager (Sydney Bioinformatics; http://www.angis.org.au/). This allowed the design, in highly conserved regions of VP1, of one sense primer (VP1-All-Sn) and three antisense primers (VP1-A-Ab, VP1-B-Ab, and VP1-C-Ab) to cover three different species (HEV-A, -B, and -C) ( Table 1) . Primer sequences were evaluated using the Sigma DNA calculator (Sigma; http://www.sigma-genosys.com/calc/dnacalc.asp) and synthesized by Sigma-Aldrich (Sydney, Australia).
RT-PCR, sequencing, and analysis of complete VP1 genes. Viral RNA was extracted from 200 l of virus-infected cell culture supernatant by use of a High Pure viral RNA kit (Roche Applied Science, Mannheim, Germany) according to the manufacturer's procedures and eluted with 50 l elution buffer. RT was performed under the following conditions: 22°C for 5 min, 50°C for 40 min, 72°C for 10 min, and 4°C for 5 min. Each RT mix contained 10 l RNA, 1 l deoxynucleoside triphosphates (dNTPs) (10 mM concentration of each dNTP), 4 l 5ϫ first-strand buffer, 1 l dithiothreitol (0.1 M), 0.5 l SuperScript III reverse transcriptase (Invitrogen, CA), 0.5 l RNasin Plus RNase inhibitor (Promega, Madison, WI), 1 l random primers (hexamers) (200 ng l Ϫ1 ) (Roche Applied Science, Mannheim, Germany), and water to 20 l. The cDNA was stored at Ϫ70°C.
The complete VP1 genes of 37 isolates, providing one or two examples of each of our commonest 20 serotypes, were sequenced in two fragments by use of published primers (17) . These were primer pairs 486-488 and 487-489 for HEV-A, primer pairs 490-492 and 491-493 for HEV-B, and primer pairs 494-496 and 495-497 for HEV-C. Primer 492 was modified to GGR TTI GTN GAI GWY TGC CA (R is A or G, I is deoxyinosine, N is A, C, G, or T, W is A or T, and Y is C or T) (modifications are shown in italics). PCR was performed using an AmpliTaq DNA polymerase kit (Appled Biosystems, Foster City, CA) and the following cycling conditions: 95°C for 10 min; 35 cycles of 94°C for 30 s, 48°C for 30 s, and 72°C for 90 s; 72°C for 10 min; and a hold at 22°C. The PCR mixture contained the following: 2 l template cDNA, 0.4 l each of forward (100 pmol l ), and water to 50 l. PCR products (10 l) were analyzed by electrophoresis on 2% ethidium bromide-stained agarose gels. For sequencing, PCR products of the appropriate size that produced visible bands upon UV illumination were further purified using a PCR product presequencing kit (USB Corporation, Cleveland, OH) according to the manufacturer's procedures. These products were sequenced using a BigDye Terminator (version 3.1) cycle sequencing kit and an ABI Prism 3100 genetic analyzer (Applied Biosystems, Foster City, CA). Sequences of the two fragments of each isolate were assembled, and the previously tested serotype was confirmed by pairwise comparison of the complete VP1 sequence with a database containing VP1 sequences for the prototype and variant strains of all known HEV serotypes (18) .
Serotype-specific probe design for VP1. After sequencing of the complete VP1 regions of 37 isolates and alignment of these VP1 sequences with at least 600 bases of VP1 sequence from GenBank for each of the 20 serotypes, using the ClustalW tool in Biomanager (Sydney Bioinformatics), four serotype-specific probes per serotype were designed in relatively conservative regions of VP1 VP1-E17-Sp1 The database of prototype strains is based on previously published sequences (23), except for EV94 (GenBank accession no. EF107097). The sequence lengths for alignment were at least 600 bases.
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on July 10, 2017 by guest http://jcm.asm.org/ (Table 1) for use in RLB. Probe sequences were evaluated using the Sigma DNA calculator (Sigma), and the probe specificity was confirmed by a BLASTn search in Biomanager. All probes were synthesized by Sigma-Aldrich (Sydney, Australia). RT-PCR for RLB. PCR (using VP1-All-Sn, VP1-A-Ab, VP1-B-Ab, and VP1-C-Ab) was performed for all 132 isolates (the 95 isolates not sequenced in VP1 were tested blinded to prior neutralization results), using a Qiagen Hotstar Taq polymerase kit (Qiagen, Clifton Hill, Victoria, Australia) and the following cycling conditions: 95°C for 15 min; 35 cycles of 94°C for 30 s, 42°C for 30 s, and 72°C for 1 min; 72°C for 10 min; and a hold at 22°C. The PCR mixture contained the following: 2 l template cDNA, 1 l VP1-All-Sn (100 pmol l RLB hybridization assay. The RLB assay was performed as previously described, with minor modifications (10) . The PCR product (30 l) was halved for hybridization over the two membranes, each of which was bound to 40 probes (4 probes for each of 10 serotypes) (Fig. 1) . Briefly, the PCR product was hybridized with membrane-bound probes at 58°C for 1 h, and the two membranes were washed separately twice (10 min each time) at 58°C with prewarmed (58°C) 2ϫ SSPE (1ϫ SSPE is 0.18 M NaCl, 10 mM NaH 2 PO 4 , and 1 mM EDTA [pH 7.7])-0.5% sodium dodecyl sulfate (SDS) and incubated in 15 ml of streptavidinperoxidase conjugate (Roche Diagnostics, Mannheim, Germany) diluted 1:4,000 in 2ϫ SSPE-0.5% SDS for 60 min at 42°C. These two membranes were further washed with 2ϫ SSPE-0.5% SDS at 42°C and then with 2ϫ SSPE at 25°C. If present, bound PCR products were detected by chemiluminescence, using ECL detection liquid (GE Healthcare Limited, Buckinghamshire, United Kingdom), and visualized by exposure for 20 min to an X-ray film (Hyperfilm; GE Healthcare Limited, Buckinghamshire, United Kingdom).
Identification of isolates negative by RLB. For isolates that were negative using the RLB assay, a modified species-specific RT-PCR amplification method (17) Table 1 for description and targets of probes listed on the left). The first membrane (shown here) was bound with 40 probes (4 probes for each of 10 common serotypes), while the second (not shown) was bound with 40 probes for the other 10 common serotypes. Conventional serotype-RT-PCR-RLB results for the isolates shown, from left to right, were CVA9 (positive control), CVA9, E6*, CVA9, CVA9, E6*, E3*, CVA16, CVA16, E30, CVA16, CVB1*, CVA16, CVA16, CVB1*, CVB2, CVB2, CVB2, CVB2, CVB2, CVB3, CVB3, CVB3, CVB3, CVB3, E7, E7, E7, CVB4*, E7, E7, E9, E9, E9, E9, E9, E17*, E3*, E9, E9, E11, E30, and CVA9 (positive control). Isolates marked with asterisks belong to one of the 10 common serotypes and were identified by the second membrane (data not shown).
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on July 10, 2017 by guest http://jcm.asm.org/ mining the species of each isolate, the complete VP1 gene was amplified, sequenced, and analyzed using the above methods. Nucleotide sequence accession numbers. Thirty-three new complete VP1 sequences for 37 isolates have been deposited in GenBank (Table 1) .
RESULTS AND DISCUSSION
Analysis of HEV database. A total of 6,383 HEV isolates were obtained from 1979 to 2007 from a variety of clinical samples, including cerebrospinal fluid, stools, vesicular skin lesions, throat swabs, and nasopharyngeal aspirates. These included isolates of PV (1,360 isolates, all vaccine strains), CVA (508 isolates), CVB (1,357 isolates), E (2,837 isolates), EV68 (2 isolates), EV69 (1 isolates), EV71 (91 isolates), and untypeable HEVs (227 isolates). Of these isolates, the commonest 10 serotypes were E11, PV1, CVB3, PV2, E9, CVA9, E30, CVB5, PV3, and E7, which accounted for 65.1% of isolates. The next 10 common serotypes were CVB4, CVB2, E6, CVA16, E14, E17, E18, CVB1, E3, and EV71 ( Table 2 ). The commonest 20 serotypes accounted for 87.1% (5,558/6,383 isolates) of all isolates over approximately 30 years.
Analysis of complete VP1 sequences. The original classification of HEVs (PV, CVA, CVB, and E) was based on biological activity and disease, even though HEVs are sometimes difficult to culture in vitro and serological typing using reference antisera is time-consuming and labor-intensive. The current molecular classification scheme divides HEVs into four species (HEV-A to -D): in this newer system, members of an EV species share Ͼ70% amino acid (aa) identity in P1, share Ͼ70% aa identity in the nonstructural proteins 2C and 3CD, share a limited range of host cell receptors, share a limited natural host range, have a genome base composition (CϩG) which varies by no more than 2.5%, and share a significant degree of compatibility in proteolytic processing, replication, encapsidation, and genetic recombination (6) . Recombination has been observed to occur in nature only among members of the same species, except in the 5Ј-nontranslated region (3, 12-14, 16, 19, 22) .
Molecular methods with analysis of the VP1 gene can function as an excellent surrogate for serotyping by neutralization. The principles include the following: (i) a partial or complete VP1 nucleotide sequence identity of Ն75% (Ͼ85% aa sequence identity) between a clinical EV isolate and a prototype serotype strain may be used to confirm the serotype of the clinical isolate, with the proviso that the second highest score is Ͻ70%; (ii) a best-match nucleotide sequence identity of Ͻ70% may indicate that the isolate represents an unknown (that is, new) serotype; and (iii) a sequence identity of 70 to 75% indicates that further characterization is required before the isolate can be identified firmly (18) . Using these criteria, strains of homologous serotypes can easily be distinguished from heterologous serotypes and new serotypes can be identified. Recently, 17 isolates were classified by this approach as members of 13 new HEV types, namely, EVs 79 to 88, 97, 100, and 101 (15) . Following sequencing of VP1, we applied these guidelines to identify 37 isolates before then designing serotype-specific probes; these showed that the genotypes/serotypes of these isolates obtained by sequencing corresponded with serotypes determined by neutralization.
VP1 primer and probe design. The VP1 sequences of all 86 known prototype strains, including EV94, were aligned to allow design of one sense primer (VP1-All-Sn). Three antisense primers (VP1-A-Ab, VP1-B-Ab, and VP1-C-Ab) were also designed to differentiate the three different HEV species (HEV-A, -B, and -C) ( Table 1) . To design each of the speciesspecific VP1-A-Ab, VP1-B-Ab, and VP1-C-Ab primers, VP1 sequences of 16 HEV-A, 54 HEV-B, and 13 HEV-C prototype strains were aligned ( Table 1 ). The primer lengths were 19 to 27 bases, and melting temperatures (T m ) were 59 to 62°C.
To construct probes for different common serotypes, the complete VP1 genes of 37 isolates were sequenced and analyzed (see above). After alignment of at least 600 bases of GenBank VP1 sequence for each of these 20 serotypes, together with the 37 complete VP1 genes sequenced in this project, four serotype-specific probes for each serotype were designed ( Table 1 ). The main principles for probe design were as follows: (i) a conservative region of one specific serotype was selected after verifying that the probes would cover as many strains within that serotype as possible; (ii) within the conservative region, the four probes should be homologous with the sequenced isolates, the prototype strain, and other convergent strains; (iii) the lengths of probes should be 18 to 27 bases, and the T m should be 58 to 67°C; and (iv) the specificity of all probes was confirmed by BLASTn search in Biomanager. The numbers of VP1 sequences aligned for probe design for each serotype are shown in Table 1 . For the four probes per serotype, the proportions of covered strains among all strains within the serotype ranged from 70.4 to 100% (Table 1 ). These data demonstrate that four probes per serotype are capable of capturing the majority of serotype strains.
Validation of primers and serotype-specific probes by RT-PCR-RLB. PCR was performed using primers VP1-All-Sn, VP1-A-Ab, VP1-B-Ab, and VP1-C-Ab to amplify the VP1 gene. For the first membrane, bound with 40 probes for 10 common serotypes, one sequenced CVA9 isolate (GenBank accession no. FJ868282) was used as the positive control to determine the location of the first probe (VP1-CVA9-Sp1) and the locations of the first and last samples of the RLB readout on the film (Fig. 1) . Similarly, one sequenced E6 isolate (GenBank accession no. FJ868294) was chosen as the positive control for the second membrane, bound with 40 probes of the other 10 common serotypes (not shown).
After hybridization with serotype-specific probes for each of the commonest 20 serotypes, the RLB assay results were concordant with the serological identification for 131 isolates, which meant that at least one probe among the four serotypespecific probes detected each isolate ( Table 2 ; Fig. 1 ). One isolate, previously identified as E14 by serotyping but negative by RLB, was confirmed as E25 by a modified species-specific RT-PCR amplification method (17) showing it as HEV-B and by VP1 sequencing (GenBank accession no. FJ868313). Repeat conventional serotyping showed that the isolate was E25, confirming the genotype.
Since the RLB assay cannot distinguish between sequences with a one-base difference, the probes for some serotypes that contain sequences with only one base difference from each other showed at least one positive result with PCR products (Fig. 1) . However, given the specificity of the probes, any one among four probes per serotype can confirm the specific serotype/genotype of each isolate.
Most recently, Susi et al. (27) developed a straightforward assay for the rapid typing of HEVs by use of oligonucleotide arrays in microtiter wells. In their studies, 10 probes for 10 different HEV reference strains were designed and employed. Furthermore, they used serotype consensus oligonucleotide probes for CVA9 to detect 25 CVA9 isolates. Both this and our studies show that such methods could potentially be extended to cover all known HEV serotypes. Theoretically, this strategy can extend to other RNA virus detection and identification procedures.
Conclusion. In this study, we successfully used RT-PCR-RLB to identify 131/132 HEV isolates belonging to the commonest 20 serotypes detected by neutralization at our institution; the exception was an E25 isolate, a relatively uncommon serotype. Genotyping by RT-PCR-RLB complements traditional serotyping methods and VP1 sequencing and has the advantages of convenience, speed, and accuracy. This will allow examination of specific HEV serotypes or genotypes associated with outbreaks and significant disease. The ease and low cost of this RT-PCR-RLB strategy will improve the diagnosis and epidemiological investigation of enteroviral infections and outbreaks where other typing methods are unavailable.
